Class II ยท Moderate risk
Duloxetine Delayed-Release Capsules
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
1 recalls, newest first
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit